Kruijf et al. confirmed that NKG2D ligand (NKG2DL) is often highly expressed in BC, and NKG2DL can bind to the activating NKG2D (KLRK1) receptor present on NK cells and subsets of T cells, thus initiating the immune response and playing a crucial role in tumor immune editing in BC34. This evidence concerns the gene KLRK1 and breast cancer.